Abstract
The revised WHO classification 2016 of central nervous system tumours incorporates molecular biomarkers in addition to histological features in an « integrated diagnosis ». Thus, it refines classification with more homogenous diagnosis groups in order to improve prognosis and to guide treatment, notably for gliomas. This article firstly summarized the new concept of this revised classification, some basis of the molecular genetics of gliomas and practical application of the « integrated diagnosis ». It analyses the impact of this classification on the diagnosis and outcome of gliomas performed at the University Institute of Pathology - CHUV, Lausanne from October 2015 to November 2016.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
